Anti-Insulin Receptor (α subunit) [Clone 83-14]

IM-9 lymphocytes

PBS, pH 7.4.

Liquid

This antibody is manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody is stable for at least one (1) year at -20°C to -70°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.

Next Day 2-8°C

Mouse Monoclonal Antibody specific to human insulin receptor; low-level cross-reactivity with bovine and rabbit insulin receptor.

Anti-Insulin Receptor (α-subunit) [Clone 83-14]
Overview of the Insulin Receptor (INSR / CD220)
The Insulin Receptor (INSR), also known as CD220, is a high-affinity receptor tyrosine kinase essential for regulating glucose homeostasis and lipid metabolism. It exists as a heterotetramer consisting of two extracellular alpha (α) subunits and two transmembrane beta (β) subunits. Upon insulin binding to the α-subunit, the receptor undergoes a conformational change that activates the intrinsic kinase activity of the β-subunits, triggering the PI3K/Akt and MAPK signaling pathways.

Specificity and Epitope Mapping of Clone 83-14 Clone 83-14 is a well-characterized mouse monoclonal antibody (IgG2a) that specifically recognizes the extracellular alpha subunit of the human insulin receptor. Technical mapping has localized its binding epitope to amino acids 469–592 (encoded by exons 7 and 8). Unlike many other clones, 83-14 is highly specific for the human receptor and shows no cross-reactivity with the rat insulin receptor or the closely related human Type 1 IGF receptor (IGF-1R), making it an ideal tool for clean, targeted research¹.

Functional Utility: Inhibition and Stimulation One of the most valuable characteristics of Clone 83-14 is its dual-action functional capability. It is widely utilized in scientific literature as a:

- Potent Inhibitor: It can block insulin binding by approximately 80%, serving as a powerful tool for studies on receptor blocking and competitive binding assays.

- Insulin-like Agonist: In specific carrier-free formulations, Clone 83-14 can act as a surrogate agonist, triggering receptor phosphorylation and downstream signaling even in the absence of insulin. This makes it highly relevant for research into insulin resistance syndromes and mutant receptor activation.

Applications in Research & Drug Delivery
Beyond standard validated applications like Western Blot (WB) and Immunoprecipitation (IP), Clone 83-14 has gained significant attention in Blood-Brain Barrier (BBB) research. It is recognized as one of the most effective transport vectors for delivering pharmaceutical payloads across the BBB via receptor-mediated transcytosis. Whether you are investigating Type 2 Diabetes (T2D), metabolic disorders, or oncogenic signaling, Leinco’s Clone 83-14 provides the high purity and specificity required for reproducible results.

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically rUniProtKB:P15208, PubMed:12138094, PubMed:16314505, PubMed:16831875, PubMed:8257688, PubMed:8276809, PubMed:8452530, PubMed:9428692}.

1.) Journal of Biology Chemistry Volume 265, Issue 17, 15 June 1990, Pages 9970-9977
2.) Soos et al. (1986) Biochem J 235: 199.
3.) Brindle et al. (1990) Biochem J 268: 615.
4.) Prigent et al. (1990) J Biol Chem 265: 9970